Marked Increase in Pediatric RSV Hospitalizations Seen Postpandemic
18 Jun 2024
VaccineClinical Result
TUESDAY, June 18, 2024 -- Hospital volumes for pediatric respiratory syncytial virus (RSV) rose significantly following the pandemic, along with the need for advanced respiratory support in older children with fewer comorbidities, according to a study published online June 13 in JAMA Network Open.
Zachary A. Winthrop, M.D., from Boston Children’s Hospital, and colleagues analyzed demographics, respiratory support modes, and clinical outcomes of children with RSV infections at tertiary pediatric hospitals (2017 to 2023) using data from 288,816 children aged 5 years and younger treated for RSV at 48 freestanding U.S. children’s hospitals registered in the Pediatric Health Information System.
The researchers found that RSV hospital presentations increased from 39,698 before the COVID-19 pandemic to 94,347 after the pandemic, which was accompanied by an 86.7 percent increase in hospitalizations (50,619 versus 27,114). Compared with prepandemic, in 2022 to 2023, children were older (median age, 11.3 versus 6.8 months) and had fewer comorbidities (17.6 versus 21.8 percent). In 2022 to 2023, there was a 70.1 percent increase in advanced respiratory support (9,094 versus 5,340).
"Although these trends need to be evaluated in subsequent years, this study highlights possible epidemiologic shifts and trends in respiratory support use that may help inform guidelines and expanded age considerations for new RSV vaccines as they become more widely available," the authors write.
Abstract/Full Text
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.